920
Participants
Start Date
October 31, 2025
Primary Completion Date
May 31, 2029
Study Completion Date
May 31, 2033
LY4064809
Administered orally
Placebo
Administered orally
Ribociclib
Administered orally
Palbociclib
Administered orally
Abemaciclib
Administered orally
Anastrozole
Administered orally
Letrozole
Administered orally
Exemestane
Administered orally
Fulvestrant
Administered intramuscular
Taichung Veterans General Hospital, Taichung
National Cheng Kung University Hospital, Tainan City
Fundación Innovaciencia, Rosario
Lake Macquarie Private Hospital, Newcastle
Goulburn Valley Health, Shepparton
St. John of God Subiaco Hospital, Subiaco
National Taiwan University Hospital, Taipei
Memorial Sloan Kettering Cancer Center, New York
Taipei Veterans General Hospital, Taipei
Summit Cancer Care, PC, Savannah
Mid Florida Hematology and Oncology Center, Orange City
Koç Üniversitesi Hastanesi, Istanbul
Clermont Oncology Center, Clermont
Yeditepe Üniversitesi Koşuyolu Hastanesi, Istanbul
Ege Universitesi Hastanesi, Bornova
Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Essen
Accellacare - DuPage, Downers Grove
Chi Mei Medical Center, Tainan City
Highlands Oncology Group, Springdale
Parkland Health and Hospital System, Dallas
UT Southwestern Medical Center, Dallas
The University of Arizona Cancer Center - North Campus, Tucson
Universitaetsklinikum Erlangen, Erlangen
Marin Cancer Care, Greenbrae
Good Samaritan Regional Medical Center, Corvallis
Beijing Cancer hospital, Beijing
The First Hospital of Jilin University, Changchun
Fudan University Shanghai Cancer Center, Shanghai
Tianjin Medical University Cancer Institute & Hospital, Tianjin
Fujian Medical University Union Hospital, Fuzhou Fujian
Fujian Cancer Hospital, Fuzhou
Xiangya Hospital Central South University, Changsha
The First People's Hospital of Changde City, Changde
Tongji Hospital Tongji Medical,Science & Technology, Wuhan
Anyang Cancer Hospital, Anyang
Guangdong Provincial People's Hospital, Guangzhou
Cancer Hospital of Shantou University Medical College, Shantou
Dana-Farber Cancer Institute, Boston
Jiangmen Center Hospital, Jiangmen
Gangnam Severance Hospital, Yonsei University Health System, Gangnam-gu
Korea University Anam Hospital, Seoul
Severance Hospital, Yonsei University Health System, Seoul
Asan Medical Center, Seoul
Adana City Hospital, Adana
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi, Ankara
Ankara University Health Practice and Research Hospitals, Ankara
Collaborators (1)
Pfizer
INDUSTRY
Eli Lilly and Company
INDUSTRY